Home >> Signaling Pathways >> MAPK Signaling

MAPK Signaling

Products for  MAPK Signaling

  1. Cat.No. Product Name Information
  2. GC68350 Tinlorafenib Tinlorafenib  Chemical Structure
  3. GC67964 Exarafenib Exarafenib  Chemical Structure
  4. GC67905 ERK1/2 inhibitor 7 ERK1/2 inhibitor 7  Chemical Structure
  5. GC67800 B-Raf IN 11 B-Raf IN 11  Chemical Structure
  6. GC65978 B-Raf IN 10 B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity. B-Raf IN 10  Chemical Structure
  7. GC65949 GNE-9815 GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers. GNE-9815  Chemical Structure
  8. GC65917 Andrograpanin Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits anti-inflammatory and anti-infectious properties. Andrograpanin  Chemical Structure
  9. GC65510 ERK1/2 inhibitor 1 ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively. ERK1/2 inhibitor 1  Chemical Structure
  10. GC65479 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity. PROTAC B-Raf degrader 1  Chemical Structure
  11. GC65329 EW-7195 EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung. EW-7195  Chemical Structure
  12. GC65303 Jaspamycin Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin  Chemical Structure
  13. GC65298 DMX-5804 DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804  Chemical Structure
  14. GC65297 MW-150 MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150  Chemical Structure
  15. GC64904 MAP855 MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2. MAP855  Chemical Structure
  16. GC64828 PLX7922 PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines. PLX7922  Chemical Structure
  17. GC64634 MLK-IN-1 MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1. MLK-IN-1  Chemical Structure
  18. GC64580 MMI-0100 MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100  Chemical Structure
  19. GC64550 B-Raf IN 2 B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer. B-Raf IN 2  Chemical Structure
  20. GC64496 EF24 EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK. EF24  Chemical Structure
  21. GC64460 8-Chloro-cAMP 8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity. 8-Chloro-cAMP  Chemical Structure
  22. GC64292 MS432 MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively. MS432  Chemical Structure
  23. GC64287 SR15006 SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells). SR15006  Chemical Structure
  24. GC64035 Hirsutenone Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone  Chemical Structure
  25. GC63903 (E)-Osmundacetone (E)-Osmundacetone is the isomer of Osmundacetone. (E)-Osmundacetone  Chemical Structure
  26. GC49700 Takeda-6d Takeda-6d  Chemical Structure
  27. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  28. GC63700 5,6,7-Trimethoxyflavone 5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone  Chemical Structure
  29. GC63680 MLKL-IN-2 MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i). MLKL-IN-2  Chemical Structure
  30. GC63569 HPK1-IN-4 HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunotherapy tool compound. HPK1-IN-4  Chemical Structure
  31. GC63554 PD0325901-O-C2-dioxolane PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader. PD0325901-O-C2-dioxolane  Chemical Structure
  32. GC63459 ERK-IN-3 benzenesulfonate ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations. ERK-IN-3 benzenesulfonate  Chemical Structure
  33. GC63441 CC-99677 CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). CC-99677  Chemical Structure
  34. GC63425 Zunsemetinib Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib  Chemical Structure
  35. GC63317 HPK1-IN-8 HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1. HPK1-IN-8  Chemical Structure
  36. GC63264 Zapnometinib Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib  Chemical Structure
  37. GC63176 Rp-cAMPS sodium salt Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 ?M and 4.5 ?M, respectively) antagonist. Rp-cAMPS sodium salt  Chemical Structure
  38. GC63144 PF-05381941 PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively. PF-05381941  Chemical Structure
  39. GC63059 MAP4K4-IN-3 MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. MAP4K4-IN-3  Chemical Structure
  40. GC63006 HPK1-IN-7 HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1. HPK1-IN-7  Chemical Structure
  41. GC63000 Gypenoside L Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L  Chemical Structure
  42. GC49440 ML-9 A PKB/Akt inhibitor ML-9  Chemical Structure
  43. GC49285 Adenosine 5’-methylenediphosphate (hydrate) An inhibitor of ecto-5’-nucleotidase Adenosine 5’-methylenediphosphate (hydrate)  Chemical Structure
  44. GC49265 PKI (14-22) amide (myristoylated) (trifluoroacetate salt) A PKA inhibitor PKI (14-22) amide (myristoylated) (trifluoroacetate salt)  Chemical Structure
  45. GC49241 Methyl Diethyldithiocarbamate An active metabolite of disulfiram Methyl Diethyldithiocarbamate  Chemical Structure
  46. GC49186 O-Demethyl Apremilast An active metabolite of apremilast O-Demethyl Apremilast  Chemical Structure
  47. GC49150 Tpl2 Kinase Inhibitor (hydrochloride) A Tpl2 inhibitor Tpl2 Kinase Inhibitor (hydrochloride)  Chemical Structure
  48. GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines. SM1-71  Chemical Structure
  49. GC62528 (Rac)-Hesperetin (Rac)-Hesperetin is the racemate of Hesperetin. (Rac)-Hesperetin  Chemical Structure
  50. GC62514 HPK1-IN-3 HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3  Chemical Structure
  51. GC62504 RAS/RAS-RAF-IN-1 RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity. RAS/RAS-RAF-IN-1  Chemical Structure
  52. GC62497 TAK1-IN-2 TAK1-IN-2 is a potent and selective TAK1 inhibitor, with an IC50> of 2 nM. TAK1-IN-2  Chemical Structure
  53. GC62492 CC-90001 CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001  Chemical Structure
  54. GC62448 Rineterkib hydrochloride Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. Rineterkib hydrochloride  Chemical Structure
  55. GC62426 ASK1-IN-2 ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM. ASK1-IN-2  Chemical Structure
  56. GC62404 p38α inhibitor 2 p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2  Chemical Structure
  57. GC62315 MKK7-COV-9 MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM. MKK7-COV-9  Chemical Structure
  58. GC62269 RRD-251 RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities. RRD-251  Chemical Structure
  59. GC62229 ERK-IN-3 ERK-IN-3 is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations. ERK-IN-3  Chemical Structure
  60. GC62206 PLX-4720-d7 PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf. PLX-4720-d7  Chemical Structure
  61. GC62146 XST-14 XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects. XST-14  Chemical Structure
  62. GC61941 Eudesmin Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin  Chemical Structure
  63. GC61865 Cearoin Cearoin increases autophagy and apoptosis through the production of ROS and the activation of ERK. Cearoin  Chemical Structure
  64. GC61849 PKI 14-22 amide,myristoylated TFA PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion. PKI 14-22 amide,myristoylated TFA  Chemical Structure
  65. GC61819 MK2-IN-3 MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3  Chemical Structure
  66. GC61747 Sp-cAMPS Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS  Chemical Structure
  67. GC61512 PKA Inhibitor Fragment (6-22) amide TFA PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA  Chemical Structure
  68. GC61485 Raf inhibitor 2 Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. Raf inhibitor 2  Chemical Structure
  69. GC61466 DMU-212 DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active. DMU-212  Chemical Structure
  70. GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. GW806742X hydrochloride  Chemical Structure
  71. GC48920 β-Carboline-1-carboxylic Acid An alkaloid with diverse biological activities β-Carboline-1-carboxylic Acid  Chemical Structure
  72. GC48652 Olomoucine II A CDK inhibitor Olomoucine II  Chemical Structure
  73. GC48469 Moexipril-d5 An internal standard for the quantification of moexipril Moexipril-d5  Chemical Structure
  74. GC48381 5'-pApA (sodium salt) A linearized form of cyclic di-AMP 5'-pApA (sodium salt)  Chemical Structure
  75. GC48329 PKA Inhibitor (5-24) (trifluoroacetate salt) A synthetic peptide inhibitor of PKA PKA Inhibitor (5-24) (trifluoroacetate salt)  Chemical Structure
  76. GC47931 PDE4B Inhibitor A PDE4B inhibitor PDE4B Inhibitor  Chemical Structure
  77. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate)  Chemical Structure
  78. GC47166 Dabrafenib-d9 An internal standard for the quantification of dabrafenib Dabrafenib-d9  Chemical Structure
  79. GC47088 Cilostazol-d4 An internal standard for the quantification of cilostazol Cilostazol-d4  Chemical Structure
  80. GC47045 Carvedilol-d5 An internal standard for the quantification of carvedilol Carvedilol-d5  Chemical Structure
  81. GC46808 ADTL-EI1712 A dual ERK1 and ERK5 inhibitor ADTL-EI1712  Chemical Structure
  82. GC46554 2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate 2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate is a cAMP analog that can be covalently coupled to acetylcholinesterase. 2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate  Chemical Structure
  83. GC60886 GSK356278 A selective PDE4 inhbitor GSK356278  Chemical Structure
  84. GC60812 ERK1/2 inhibitor 2 ERK1/2 inhibitor 2 (Example 1) is a potent dual ERK1/2 inhibitor. ERK1/2 inhibitor 2 has anti-cancer activity. ERK1/2 inhibitor 2  Chemical Structure
  85. GC60393 (-)-Zuonin A (-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively. (-)-Zuonin A  Chemical Structure
  86. GC60262 N-Feruloyloctopamine N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK. N-Feruloyloctopamine  Chemical Structure
  87. GC60037 A-3 hydrochloride A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. A-3 hydrochloride  Chemical Structure
  88. GC39815 Semapimod tetrahydrochloride Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod tetrahydrochloride  Chemical Structure
  89. GC39485 CK2/ERK8-IN-1 A dual inhibitor of CK2 and ERK8 CK2/ERK8-IN-1  Chemical Structure
  90. GC39325 2,5-Dihydroxyacetophenone 2,5-Dihydroxyacetophenone, isolated from Rehmanniae Radix Preparata, inhibits the production of inflammatory mediators in activated macrophages by blocking the ERK1/2 and NF-κB signaling pathways. 2,5-Dihydroxyacetophenone  Chemical Structure
  91. GC50502 RI-STAD 2 AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable RI-STAD 2  Chemical Structure
  92. GC50501 STAD 2 AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable STAD 2  Chemical Structure
  93. GC50407 st-Ht31 P Negative control for st-Ht31 st-Ht31 P  Chemical Structure
  94. GC50406 st-Ht31 Inhibits PKA/AKAP interactions; cell permeable st-Ht31  Chemical Structure
  95. GC50400 CC 401 dihydrochloride High affinity JNK inhibitor; also inhibits HCMV replication CC 401 dihydrochloride  Chemical Structure
  96. GC50316 Org 48762-0 Selective p38α/β inhibitor; orally bioavailable Org 48762-0  Chemical Structure
  97. GC50295 TL4-12 Potent MAP4K2 (GCK) inhibitor TL4-12  Chemical Structure
  98. GC50294 RMM 46 MSK/RSK family kinase inhibitor RMM 46  Chemical Structure
  99. GC50252 PF 06260933 dihydrochloride MAP4K4 (HGK) inhibitor; also inhibits MINK and TNIK PF 06260933 dihydrochloride  Chemical Structure
  100. GC50181 CW 008 PKA signaling activator; promotes osteogenesis from hMSCs CW 008  Chemical Structure
  101. GC46123 Comprehensive Kinase Screening Library For screening of a variety of kinase inhibitors Comprehensive Kinase Screening Library  Chemical Structure

Items 1 to 100 of 492 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction